All In Biotech

Drug Trial Radar · NCT06926582

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Clinical Efficacy and Safety of HS-10374 in Adult Patients With Mild-to-moderate Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 305 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

305

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Jul 9, 2026

Study completion Dec 9, 2026

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • HS-10374 6mg tabletsDrug

    Administered orally QD for 12 weeks

  • HS-10374-matched placebo tabletsDrug

    Administered orally QD for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients achieving sPGA 0/1 with at least 2 points improvement from baseline at Week 12Time frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Dermatology Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.